Efficacy and safety of epicutaneous immunotherapy for severe egg allergy

Efficacy and safety of epicutaneous immunotherapy for severe egg allergy - Epicutaneous immunotherapy for egg allergy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022348

Enrollment

Registered

2016-05-24

Start date

2016-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food allergy

Interventions

Cutaneous application of ovomucoid-containing hydrogel patch 12 hours a day for 24 weeks Cutaneous application of hydrogel patch without containing antigen 12 hours a day for 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Egg allergy diagnosed by oral food challenge (OFC) without tendency of natural outgrow 2) Cooked egg dose threshold of OFC =<2g

Exclusion criteria

Exclusion criteria: 1) Allergy to soy and milk 2) Large change in intake levels of egg before 3 months of the trial 3) Complication or past history of heart, liver and kidney diseases 4) Uncontrolled asthma or atopic dermatitis

Design outcomes

Primary

Measure	Time frame
Dose threshold in oral egg challenge after 24 weeks of treatment	—

Secondary

Measure	Time frame
Safety: local reaction, systemic immediate-type allergic reaction and other	—

Countries

Japan

Contacts

Public ContactYu Kuwabara

National Hospital Organization Mie National Hospital Allergy center

yu_surrealist@hotmail.co.jp+81592322531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026